CN1130212C - Medicine for treating abdominal node and its preparing process - Google Patents
Medicine for treating abdominal node and its preparing process Download PDFInfo
- Publication number
- CN1130212C CN1130212C CN 00132276 CN00132276A CN1130212C CN 1130212 C CN1130212 C CN 1130212C CN 00132276 CN00132276 CN 00132276 CN 00132276 A CN00132276 A CN 00132276A CN 1130212 C CN1130212 C CN 1130212C
- Authority
- CN
- China
- Prior art keywords
- medicine
- rhizoma
- shares
- medicinal residues
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to medicine for treating a lump symptom, which is characterized in that the present invention is formed by that 5 to 10 shares of prepared pinellia, 2 to 5 shares of coptis roots, 4 to 8 shares of scutellaria, 5 to 8 shares of dried ginger, 2 to 5 shares of raw sun-dried ginseng, 3 to 6 shares of prepared licorice, 5 to 8 shares of fructus and 4 to 8 shares of citrusaurantiuml are used as raw materials, an ethanol solution is used for extraction in the mode of back flow, and powder is made in the mode of spray drying; the ethanol solution is used for spraying, granulation and drying, and medicine granules are loaded in capsules. The test of the mediicne effect and the toxicity of the medicine is carried out through animals, and the mediicne effect and the toxicity both achieves national requirements. The present invention proves that the medicine has therapeutic action on lump symptoms, such as gastric ulcer, etc.
Description
The present invention relates to a kind of medicine for the treatment of painful abdominal mass, specifically is the Chinese patent medicine that raw material is made with the Chinese herbal medicine.
The invention still further relates to the preparation method of this medicine.
Painful abdominal mass is a kind of common frdquently encountered disease, typically refer to the incoordination between the spleen and stomach lifting caused distension and fullness in the abdomen of lacking of proper care, indigestion and loss of appetite lack of appetite, noisy stomachache, the heating installation singultus, nausea and vomiting, it is uncomfortable to defecate, and this disease is difficult for being much accounted of, untimely again treatment, body constitution descends gradually, with the passage of time, even can develop into other disease.
At present this disease there is not specific drug, most with western medicine, but specific aim is poor, and effect is undesirable.
The object of the present invention is to provide a kind of have invigorating the spleen and regulating the stomach, lowering the adverse QI with bitter drugs and dispersing the accumulated pathogen with pungent drugs, the medicine of the treatment painful abdominal mass of relieving distension and oppression, thus can effectively treat this kind disease.
The invention still further relates to the preparation method of this medicine.
The objective of the invention is to realize by following technical proposal:
The medicine of treatment painful abdominal mass is characterized in that it is the medicament of being made by the following weight proportion raw material:
Rhizoma Pinelliae Preparatum 5-10 part Rhizoma Coptidis 2-5 part Radix Scutellariae 4-8 part Rhizoma Zingiberis 5-8 part
Radix Ginseng 2-5 part Radix Glycyrrhizae Preparata 3-6 part Fructus Jujubae 5-8 part Fructus Aurantii Immaturus 4-8 part.
Pharmaceutical formulation preferred weight ratio range of the present invention:
Rhizoma Pinelliae Preparatum 7-9 part Rhizoma Coptidis 3-4 part Radix Scutellariae 5-6 part Rhizoma Zingiberis 6-7 part
Radix Ginseng 3-4 part Radix Glycyrrhizae Preparata 4-5 part Fructus Jujubae 6-7 part Fructus Aurantii Immaturus 5-6 part.
Medicine optimum weight proportioning of the present invention is:
6.2 parts of 5.2 portions of Rhizoma Zingiberiss of 3.7 parts of Radix Scutellariaes of 7.8 portions of Rhizoma Coptidis of the Rhizoma Pinelliae
Shine 5.2 parts of 6.3 parts of Fructus Aurantii Immaturuss of ginseng 4.5 portions of Fructus Jujubaes of 3.0 parts of Radix Glycyrrhizae Preparatas.
Medicine of the present invention is the capsule formulation on the pharmaceutics.
Chinese herbal medicine of the present invention is by theory of Chinese medical science, through scientific experiments, reasonable compatibility is selected, wherein Rhizoma Pinelliae Preparatum is the process of preparing Chinese medicine processed goods of the aroid Rhizoma Pinelliae, Rhizoma Coptidis is the dry rhizome of buttercup plant Rhizoma Coptidis Coptis deltoidea C.Y.Cheng et Hsiao or Yun Kunlian, Radix Scutellariae is the dry root of labiate Radix Scutellariae, Rhizoma Zingiberis is the dry rhizome of zingiber, Radix Ginseng is an Araliaceae Radix Ginseng dry root, Radix Glycyrrhizae Preparata is the leguminous plant Radix Glycyrrhizae Preparata, the process of preparing Chinese medicine processed goods of bloated fruit Radix Glycyrrhizae Preparata or light fruit Radix Glycyrrhizae Preparata, Fructus Jujubae is the dry mature fruit of Rhamnaceae plant Fructus Jujubae, Fructus Aurantii Immaturus is the dry young fruit of rutaceae Citrus aurantium Linn. and variety or Fructus Citri sinensis.
Rhizoma Pinelliae Preparatum is a monarch drug, and Rhizoma Coptidis, Radix Scutellariae, Rhizoma Zingiberis are ministerial drug, and Radix Ginseng, Fructus Jujubae, Fructus Aurantii Immaturus are adjuvant drug, Radix Glycyrrhizae Preparata is a messenger drug, monarch, minister, helps, makes compatibility reasonable, and function cures mainly, invigorating the spleen and regulating the stomach, lowering the adverse QI with bitter drugs and dispersing the accumulated pathogen with pungent drugs, it is full that the painful abdominal mass that disappears is fallen, and cures mainly: incoordination between the spleen and stomach, the lifting caused distension and fullness in the abdomen of lacking of proper care, indigestion and loss of appetite lack of appetite, noisy stomachache, the belch singultus, nausea and vomiting, it is uncomfortable to defecate.
Preparation method of the present invention:
(a) 2-5 part Rhizoma Coptidis is added doubly 70% alcoholic solution of 8-10, heat according to a conventional method reflux, extract, three times, each 1-2 hour, cross the elimination medicinal residues, merging filtrate, decompression recycling ethanol concentrates spray-dried powder process with filtrate again;
(b) 2-5 part Radix Ginseng is added doubly 50% alcoholic solution of 8-10, heat according to a conventional method reflux, extract, three times, each 2-3 hour, cross the elimination medicinal residues, merging filtrate, decompression recycling ethanol concentrates filtrate again; The spray-dried powder body of making;
(c) with 5-10 part Rhizoma Pinelliae Preparatum, 5-8 part Rhizoma Zingiberis, 4-8 part Radix Scutellariae, 5-8 part Fructus Jujubae, 3-6 part Radix Glycyrrhizae Preparata, the 8-10 times of decocting that 4-8 part Fructus Aurantii Immaturus and Rhizoma Coptidis medicinal residues (a) and Radix Ginseng medicinal residues (b) add drug weight boils three times, each 1-2 hour, crosses the elimination medicinal residues, merging filtrate, be evaporated to filtrate relative density 1.10-1.16 (60 ℃), concentrated medicament, spray drying powder process again;
(d) at last with the powder mix homogeneously of three of (a) and (b), (c), spray conventional method with 50% ethanol and granulate, 60 ℃ of oven dry, incapsulate, each capsule 0.5g promptly makes medicine of the present invention.
Medicine of the present invention has carried out a series of pharmacodynamics test, acute toxicity test, and long term toxicity test, its result is as follows:
One, results of pharmacodynamic test:
1, to the effect of gastric ulcer:
1.1 to the rat water logging stress the type gastric ulcer effect;
Get 27 of body weight 150-180g rats, the male and female dual-purpose, it is that machine divides three groups after 24 hours that water is can't help in fasting, experimental group is irritated two groups of the high and low dose that stomach is given medicine of the present invention, and matched group is irritated the isometric normal saline of stomach, after 18 hours, check the ulcer pathological changes, as ulcer index, carry out statistical disposition with the millimeter of ulcer length summation, it the results are shown in Table 1
Table 1 pair rat water logging stress the type gastric ulcer effect (X=SD) group dosage number of animals ulcer index suppression ratio
(g/kg) (only) (mm) (%) matched group-9 23.2 ± 4.52-experimental group I 10 9 18.7 ± 5.52 19.6 experimental group II 20 9 15.4 ± 4.77 33.5
The result shows that experimental group can obviously suppress the water logging stress gastric ulcer, compares with matched group, has significant difference P＜0.01.
1.2 effect to rat acetic acid damage type gastric ulcer:
Get 32 of body weight 150-180g rats, the male and female dual-purpose, fasting 12 hours makes with serous coat with 100% glacial acetic acid 0.05ml to contact 1 minute, next day, random packet, two groups of the high low dosages of medicine of the present invention, matched group was irritated the isopyknic continuous normal saline of stomach 11 days, checked the ulcer situation, carry out statistical disposition with the major diameter of ulcer and the equal value representation ulcer index of minor axis, it the results are shown in Table 2
The effect of table 2 pair rat acetic acid damage type gastric ulcer (the group dosage number of animals ulcer index suppression ratio of X ± SD)
(g/kg) (only) (mm) (%) matched group-11 8.0 ± 1.58-experimental group I 10 10 7.1 ± 1.32 11.3 experimental group II 20 10 6.3 ± 1.29 21.3
The result shows that experimental group can obviously suppress the damaging gastric ulcer of acetic acid, relatively has significant difference with matched group, P＜0.05.
2. to the influence of mice gastric emptying:
Getting body weight is the 20-22g mice, the male and female dual-purpose, and fasting 12 hours is freely drunk water, and adopts subcutaneous administration, and administration was irritated stomach 0.2ml 0.1% methyl orange solution after 30 minutes, measured methyl orange stomach residual rate, and it the results are shown in Table 3:
The influence of table 3 pair mice gastric emptying (the group dosage number of animals stomach residual rate of X ± SD)
(g/kg) (only) (%) matched group-11 47.82 ± 4.68 experimental group I 6.4 12 34.89 ± 8.93 experimental group II 12.8 11 32.63 ± 7.86
The result shows: 3 days medicines of the present invention of experimental group injection, can reduce methyl orange stomach residual rate, and with matched group significant difference is arranged relatively, P＜0.001.
3. to the influence of rat gastric juice composition
Get the 180-200g rat, fasting 24 hours is freely drunk water, and injects medicine of the present invention at duodenum, and matched group is given normal saline with method, gets the centrifugal mensuration supernatant calculating of gastric juice gastric juice amount and carries out gastric analysis, the results are shown in Table 4:
Table 4: to rat gastric juice determination of peptic activity result (the total acid output of the group dosage number of animals gastric juice amount pH value total acid rate gastric activity unit of X ± SD)
(g/kg), (only), (ml), (mmol/l), (umol/l), (matched group-9 3.3 ± 1.3 2.5 ± 1.1 18.7 ± 6.0 22.7 ± 8.1 181.1 ± 131.5 experimental group I 6.4 8 4.1 ± 1.0 2.6 ± 0.4 19.1 ± 4.2 21.2 ± 6.5 168.4 ± 73.8 experimental group II 12.8 12 3.4 ± 1.5 2.2 ± 0.7 16.9 ± 4.0 18.2 ± 7.2 127.4 ± 78.8 of active unit/h)
The result shows that experimental group is irritated stomach medicine of the present invention does not have obvious influence to gastric secretion, acidity and gastric activity, P＜0.05.
4. to the propulsive influence of mouse small intestine
Get 24 hours adult mices of fasting, male female half and half, measure intestinal tube length as the small intestinal total length with the medicine liquid irrigation stomach that contains 50% prepared Chinese ink, pylorus to the distance in China ink meter forward position as " prepared Chinese ink is at the enteral advance distance ", it the results are shown in Table 5:
Table 5 mouse small intestine ahead running influence (the group dosage number of animals prepared Chinese ink advance distance small intestinal total length propelling rate intestinal volume of X ± SD)
(g/kg) (only) (cm) (cm) (%) (g) matched group-10 29.7 ± 7.6 42.4 ± 7.7 70.43 ± 16.11 1.2 ± 0.13 experimental group I 6.4 10 36.4 ± 6.5 42.0 ± 4.4 86.49 ± 11.17 1.1 ± 0.13 experimental group II 12.8 10 40.7 ± 6.7 44.5 ± 3.9 91.13 ± 11.45 1.15 ± 0.10
The result shows: medicine of the present invention has remarkable increase intestinal propulsion motion, with matched group significant difference is arranged relatively, but the small intestinal volume is not had obvious influence, P＜0.01.
5. antiinflammatory action:
Get body weight 120-150g, 36 of male rats, divide 3 groups at random, every group 12, experimental group is two groups of high and low dose groups and matched group, lumbar injection pentobarbital sodium 30mg/kg anesthesia then, strange portion iodine disinfection about every mice, 75% cotton ball soaked in alcohol takes off iodine, respectively cut the long osculum of 1cm, with 40mg sterilize cotton balls implant from otch subcutaneous, behind the sealing, irritate stomach the same day and gave normal saline and medicine of the present invention continuous 6 days, opened former otch on the 7th day, and got cotton balls, reject cotton balls and fatty tissue together with connective tissue taking-up on every side, oven dry is weighed, and it the results are shown in Table 6:
Table 6 pair rat granuloma is swollen form influence group dosage number of animals granuloma dry weight suppression ratio
(g/kg) (only) (mg/100g) (%) matched group-10 33.9 ± 8.80 experimental group I 10 11 27.24 ± 4.6 19.7 experimental group II 20 11 25.3 ± 5.83 25.5
The result shows that medicine of the present invention has the obvious suppression effect to the granuloma induced by implantation of cotton pellets of rat, compares with matched group, and significant difference is arranged, and P＜0.05 illustrates that medicine of the present invention has tangible antiinflammatory action.
6. to the influence of mice with spleen deficiency body weight due to the Radix Et Rhizoma Rhei:
Get body weight 18-20g mice, male and female have concurrently, divide experiment moulding group and matched group, the moulding group is only irritated stomach with 150% Radix Et Rhizoma Rhei water decoction 0.6ml/, once a day, and continuous 8 days, matched group is fed normal saline, weigh two groups of every days, observes its sign, feces, the next day survey the anus temperature, the moulding group was divided three groups on the 9th day at random, for irritating stomach height, low dosage.Medicine matched group of the present invention plays saline with isometric life and irritates stomach, and weigh every day, the next day survey body temperature, administration is after 5 days, all animal manual muscle tests are put into 25 ℃ of water with mouse tail bolt 2g weights and are swum, meter persistent period and mice recovery situation, it the results are shown in Table 7-1,7-2,7-3.
Table 7-1 is to mice with spleen deficiency temperature influence due to the Radix Et Rhizoma Rhei (the group dosage number of animals of X ± SD) during each mouse temperature (℃)
(g/kg) (only)
Matched group-10 35.5 ± 0.49 35.8 ± 0.78 36.0 ± 0.88 model group-9 34.1 ± 0.73 experimental group I, 89 35.4 ± 0.83 34.4 ± 1.18 35.1 ± 0.44 experimental group II 16 9 35.2 ± 0.77 after (20.5 ℃) administration before (20 ℃) administration before the moulding
The result shows: medicine of the present invention and matched group compare, and P＜0.01 is compared with model group in P＜0.001.
Table 7-2 is to mice with spleen deficiency body weight influence due to the Radix Et Rhizoma Rhei (the group dosage number of animals of X ± SD) during each mouse temperature (℃)
(g/kg) (only)
Matched group-10 24.0 ± 1.61 24.7 ± 2.52 26.7 ± 2.84 model group-9 20.2 ± 1.09 experimental group I, 89 23.5 ± 2.24 21.1 ± 1.85 20.6 ± 1.82 experimental group II 16 9 21.1 ± 2.30 after (20.5 ℃) administration before (20 ℃) administration before the moulding
The result shows that medicine of the present invention and matched group relatively have significant difference P＜0.01.
Table 7-3 is to the influence of mice with spleen deficiency swimming time due to the rat (the group dosage number of animals swimming time (24 ℃ ± 1 ℃) of X ± SD)
(g/kg) (only) (min) matched group-12 19.9 ± 10.1 model group-9 10.5 ± 3.03 experimental group I 89 15.5 ± 7.26* experimental group II 16 9 19.5 ± 8.49*
The result shows: medicine of the present invention and matched group be P＜0.01 relatively.Compare * P＜0.05, * * P＜0.01 with model group.
In sum, experimental mice body weight, body temperature descend obviously during the moulding, and with loose stool, indigestion and loss of appetite, hair insufficiency of the spleen symptom such as withered, with matched group significant difference is arranged, show the moulding success, take the swimming time that medicine of the present invention can obviously prolong mice with spleen deficiency after the administration, rising body temperature, increase the mice body weight, compared significant difference, illustrate that medicine of the present invention has an obvious treatment effect to insufficiency of the spleen with matched group.
7. eating and drinking without temperance is caused the influence of mice with spleen deficiency body temperature:
Get 40 male mices and be divided into 4 groups at random, normal group is fed the Brassica oleracea L.var.capitata L. material, freely intakes model group hello Brassica oleracea L.var.capitata L. every day, the next day irritate the stomach refined lard once, each 0.5ml/, experimental group is irritated two groups of medicine high and low dose of the present invention every day separately, and feed material Brassica oleracea L.var.capitata L. is irritated stomach Adeps Sus domestica, at present, weigh every day, observes sign, feces, the next day survey the anus temperature, continuous 8 days, respectively organized fasting 24 hours on the 9th day, and, extremely located after 20 minutes with the medicine liquid irrigation stomach that contains 50% prepared Chinese ink, calculate prepared Chinese ink propelling rate, the results are shown in Table 8-1,8-2,8-3.
Table 8-1 causes the influence (during the group dosage number of animals moulding administration of X ± SD) (℃) of mice with spleen deficiency body temperature to eating and drinking without temperance
(g/kg) (only)
(21.5 ℃) matched group-10 35.4 ± 0.51 35.4 ± 0.59 model group-10 35.5 ± 0.51 32.8 ± 0.99 experimental group I 8 10 35.4 after (20.5 ℃) moulding ± 0.5 34.0 ± 1.07* experimental group II, 16 10 35.0 ± 0.41 34.3 ± 1.31** before the moulding
Compare with matched group, * * P＜0.01, * P＜0.05 are compared with horizontal type group in P＜0.001
Table 8-2 causes influence (the body weight g during the group dosage number of animals moulding administration of X ± SD) of spleen mice body weight to eating and drinking without temperance
(g/kg) (only)
Matched group-10 22.0 ± 1.71 27.6 ± 1.40 model group-10 21.9 ± 1.66 17.4 ± 1.65 experimental group I 8 10 21.8 ± 1.66 18.0 ± 1.27 experimental group II 16 10 21.8 ± 1.53 18.8 ± 1.12* after the moulding before the moulding
Compare with matched group, * P＜0.05 is compared with model group in P＜0.001
Table 8-3, to the influence of mice with spleen deficiency intestinal propulsion function, (X ± SD) group dosage number of animals adds up advance distance small intestinal sum propelling rate
(g/kg), (only), (cm), (cm), (%) matched group-10 29.3 ± 5.17 38.1 ± 3.5 25.4 ± 8.83 model group-10 30.1 ± 3.14 38.8 ± 4.3 76.0 ± 11.2 experimental group I 8 10 31.1 ± 5.97 38.0 ± 2.11 85.5 ± 11.7 experimental group II 16 10 33.1 ± 5.80 37.0 ± 3.46 89.3 ± 12.0*
With matched group, model group is P＜0.05 relatively.
In sum, medicine of the present invention can significantly increase the motion of mice with spleen deficiency intestinal propulsion, and the small intestinal volume is not had bright influence.
Two, acute toxicity test:
With medicine of the present invention kunming mice is carried out acute toxicity test, once give the toxic reaction and the death condition that are produced behind the mice, because toxicity is lower, can not survey LD50, pretend maximum tolerance determination on the one, press the 0.2ml/10g oral administration, per 4 hours once, every day totally three times, every day, dosage was amounted to crude drug amount 191g/kgd, observed reaction of animals and death condition in seven days after the administration, result of the test, after the administration 0.5 hour, activity slightly reduces or increases, fur is smooth within 7 days, and appetite does not have significant change, defecation be as good as at ordinary times, do not see that position is unusual, cry is unusual, and no amyostasia spasm is twitched, behavioral activity is normal, be the irritant reaction sensitivity to external world, no sialorrhea, shed tears and perspire no abnormal secretions, breathe moderate, nothing is become thin, and no abnormality seen and death after 14 days think that oral medicine maximum tolerated dose of mice is greater than 191/kgd, clinical usual amounts is adult's every day three times, each 1.5g, promptly every day 4.5g, suitable crude drug amount 40g, becoming body weight for humans to press 50kg calculates, clinical drug then of the present invention adult dosage 0.8g/kgd, the mice maximum tolerated dose is equivalent to crude drug amount 191g/kgd, is 239 times of clinical adult's dosage.
Three, long term toxicity test:
Examine way according to national drug, continuous 13 weeks are carried out rat and dog long term toxicity test through gastric infusion, rat medication group dosage is equivalent to the clinical application amount and is respectively 10 by weighing machine, 25 and 50 times, dog medication group dosage is equivalent to the clinical application amount and is respectively 10 and 30 times by weighing machine, does not see animal dead and other abnormal response after continuous 13 weeks, each treated animal outward appearance sign, behavioral activity are normal, appetite is good, and body weight obviously increases, and does not have statistical discrepancy between each group.
After 13 weeks and after 2 weeks of drug withdrawal, the unhelpful learning with hematology's blood biochemical of medication group and matched group checks that so each index of medication group and matched group there was no significant difference are in range of normal value at continuous use.The perusal no abnormality seen is dissected by system, the main organs coefficient is all in normal range, its main organs is done the tissue slice inspection, do not see obvious pathological change, there is not significant difference between administration group and the matched group, carry out the routine urinalysis, routine blood test, blood biochemical of dog with method and learn and Electrocardioscopy, each index of medication group and matched group are than there was no significant difference, all in range of normal value; Perusal is dissected by system, and all in range of normal value, its main organs is done the tissue slice inspection for each internal organs no abnormality seen, main organs coefficient, does not see obvious pathological change, and convalescent period is checked the internal organs no abnormality seen.
Result of the test shows, clinical drug consumption 40g every day crude drug amount of the present invention is safety.
In sum, medicine of the present invention, it has inhibition ulcer, promotes gastric emptying, increases intestinal propulsion, and secretion, acidity and the gastric activity of gastric juice do not had obvious influence, strengthens antiinflammatory action, and animals with spleen deficiency is had the obvious treatment effect.
Compared with the prior art the technology of the present invention has following advantage and effect:
A) medicine of the present invention proves that through a large amount of zooperies this medicine can obviously reduce the generation of rat water logging irritability and acetic acid calcination damage type gastric ulcer, obviously reduce the residual rate of mice stomach methyl orange, gastric secretion, acidity and gastric activity there is not obvious influence, can promote the small intestinal emptying, reduce the bullate weight of rat cotton balls internal bud, the symptom of spleen due to antagonism Radix Et Rhizoma Rhei and the eating and drinking without temperance, improve its stress ability and Small Intestine, provable thus this medicine has inhibition ulcer.
B) this medicine all meets national standard through acute toxicity test and long term toxicity test, is safe and reliable, and is without any side effects.
C) reasonable recipe, the preparation method science, effectively effective component extracting can reduce drug dose, improves drug action.
Embodiment 1:
Getting Rhizoma Coptidis 2kg, to add 16kg concentration be 70% alcoholic solution, heats according to a conventional method reflux, extract, three times, each 1 hour, cross the elimination medicinal residues, merging filtrate, decompression recycling ethanol, again filtrate is concentrated spray-dried powder process, get Radix Ginseng 5kg, adding 40kg concentration is 50% alcoholic solution, heat according to a conventional method reflux, extract, three times, each 2 hours, cross the elimination medicinal residues, merging filtrate, decompression recycling ethanol concentrates filtrate spray-dried powder process again, follow the example of Rhizoma Pinelliae 5kg, Rhizoma Zingiberis 8kg, Radix Scutellariae 4kg, Fructus Jujubae 8kg, Radix Glycyrrhizae Preparata 3kg and Fructus Aurantii Immaturus 8kg and Rhizoma Coptidis medicinal residues, the Radix Ginseng medicinal residues add 430kg water together and decoct according to a conventional method three times, each 2 hours, cross the elimination medicinal residues, merging filtrate is evaporated to the concentrated medicament of relative density of medicine liquid 1.10 (60 ℃), spray drying powder process again, at last again with the Rhizoma Coptidis powder, the Radix Ginseng powder is mixed together, with concentration is that 50% ethanol sprays granulation, 60 ℃ of oven dry, incapsulate each capsule 0.5g.
Embodiment 2:
Getting Rhizoma Coptidis 3.7kg, to add 32kg concentration be 70% alcoholic solution, heats according to a conventional method reflux, extract, three times, each 1.5 hours, cross the elimination medicinal residues, merging filtrate, decompression recycling ethanol, again filtrate is concentrated spray-dried powder process, get Radix Ginseng 3kg, adding 30kg concentration is 50% alcoholic solution, heat according to a conventional method reflux, extract, three times, each 2.5 hours, cross the elimination medicinal residues, merging filtrate, decompression recycling ethanol, filtrate is concentrated, Rhizoma Pinelliae 7.8kg is followed the example of in spray-dried powder process again, Rhizoma Zingiberis 6.2kg, Radix Scutellariae 5.2kg, Fructus Jujubae 6.3kg, Radix Glycyrrhizae Preparata 4kg and Fructus Aurantii Immaturus 5.2kg and Rhizoma Coptidis medicinal residues, the Radix Ginseng medicinal residues add 350kg water together and decoct according to a conventional method three times, each 1.5 hours, cross the elimination medicinal residues, merging filtrate is evaporated to the concentrated medicament of relative density of medicine liquid 1.14 (60 ℃), spray drying powder process again, being mixed together with Rhizoma Coptidis powder Radix Ginseng powder more at last, is that 50% ethanol sprays granulation with concentration, 60 ℃ of oven dry, incapsulate each capsule 0.5g.
Embodiment 3:
Getting Rhizoma Coptidis 5.0kg, to add 50kg concentration be 70% alcoholic solution, heats according to a conventional method reflux, extract, three times, at each 2 o'clock, cross the elimination medicinal residues, merging filtrate, decompression recycling ethanol, again filtrate is concentrated spray-dried powder process, get Radix Ginseng 2g, adding 16kg concentration is 50% alcoholic solution, heat according to a conventional method reflux, extract, three times, each 2 hours, cross the elimination medicinal residues, merging filtrate, decompression recycling ethanol, filtrate is concentrated, Rhizoma Pinelliae 10kg is followed the example of in spray-dried powder process again, Rhizoma Zingiberis 5kg, Radix Scutellariae 8kg, Fructus Jujubae 6.3kg, Radix Glycyrrhizae Preparata 6kg and Fructus Aurantii Immaturus 4kg and Rhizoma Coptidis medicinal residues, the Radix Ginseng medicinal residues add 430kg water together and decoct according to a conventional method three times, each 1 hour, cross the elimination medicinal residues, merging filtrate is evaporated to the concentrated medicament of relative density of medicine liquid 1.16 (60 ℃), spray drying powder process again, being mixed together with Rhizoma Coptidis powder Radix Ginseng powder more at last, is that 50% ethanol sprays granulation with concentration, 60 ℃ of oven dry, incapsulate each capsule 0.5g.
Claims (4)
1, the medicine of treatment painful abdominal mass is characterized in that it is the medicament of being made by the following weight proportion raw material:
Rhizoma Pinelliae Preparatum 7-9 part Rhizoma Coptidis 3-4 part Radix Scutellariae 5-6 part Rhizoma Zingiberis 6-7 part
Radix Ginseng 3-4 part Radix Glycyrrhizae Preparata 4-5 part Fructus Jujubae 6-7 part Fructus Aurantii Immaturus 5-6 part.
2, the medicine of treatment painful abdominal mass according to claim 1, wherein the weight proportion of each raw material is:
6.2 parts of 5.2 portions of Rhizoma Zingiberiss of 3.7 parts of Radix Scutellariaes of 7.8 portions of Rhizoma Coptidis of Rhizoma Pinelliae Preparatum
5.2 parts of 6.3 parts of Fructus Aurantii Immaturuss of 4.5 portions of Fructus Jujubaes of 3.0 parts of Radix Glycyrrhizae Preparatas of Radix Ginseng.
3,, it is characterized in that described medicine is the capsule formulation on the pharmaceutics according to the medicine of claim 1,2 described treatment painful abdominal mass.
4, the preparation method of the medicine of treatment painful abdominal mass according to claim 3 is characterized in that it is undertaken by following step:
(a) 3-4 part Rhizoma Coptidis is added doubly 70% alcoholic solution of 8-10, heat according to a conventional method reflux, extract, three times, each 1-2 hour, cross the elimination medicinal residues, merging filtrate, decompression recycling ethanol concentrates spray-dried powder process with filtrate again;
(b) 3-4 part Radix Ginseng is added doubly 50% alcoholic solution of 8-10, heat according to a conventional method reflux, extract, three times, each 2-3 hour, cross the elimination medicinal residues, merging filtrate, decompression recycling ethanol concentrates filtrate again; The spray-dried powder body of making;
(c) with 7-9 part Rhizoma Pinelliae Preparatum, 6-7 part Rhizoma Zingiberis, 5-6 part Radix Scutellariae, 6-7 part Fructus Jujubae, 4-5 part Radix Glycyrrhizae Preparata, the 8-10 times of decocting that 5-6 part Fructus Aurantii Immaturus and Rhizoma Coptidis medicinal residues (a) and Radix Ginseng medicinal residues (b) add drug weight boils each 1-2 hour three times, cross the elimination medicinal residues, merging filtrate is evaporated to filtrate relative density 1.10-1.16,60 ℃, concentrated medicament, spray drying powder process again;
(d) at last with the powder mix homogeneously of three of (a) and (b), (c), spray conventional method with 50% ethanol and granulate, 60 ℃ of oven dry, incapsulate, each capsule 0.5g promptly makes medicine of the present invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00132276 CN1130212C (en) | 2000-11-16 | 2000-11-16 | Medicine for treating abdominal node and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00132276 CN1130212C (en) | 2000-11-16 | 2000-11-16 | Medicine for treating abdominal node and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1293973A CN1293973A (en) | 2001-05-09 |
| CN1130212C true CN1130212C (en) | 2003-12-10 |
Family
ID=4595100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00132276 Expired - Fee Related CN1130212C (en) | 2000-11-16 | 2000-11-16 | Medicine for treating abdominal node and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1130212C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102847113A (en) * | 2012-08-30 | 2013-01-02 | 李承平 | Ginseng and coptis chinensis capsules with function of stasis removing |
| CN103479992A (en) * | 2013-10-14 | 2014-01-01 | 张桂赫 | Traditional Chinese medicine pill for treating anxiety neurosis accompanied with digestive tract symptom and preparation method thereof |
| CN106421684A (en) * | 2016-08-26 | 2017-02-22 | 广西慧投互联网金融服务有限公司 | Composition capable of diminishing inflammation and strengthening stomach |
| CN107913391B (en) * | 2016-10-11 | 2021-03-12 | 北京中医药大学东方医院 | Pharmaceutical composition for treating non-erosive gastroesophageal reflux disease and preparation method and application thereof |
| CN114767823A (en) * | 2022-04-13 | 2022-07-22 | 黄东生 | Traditional Chinese medicine for treating stomach stuffiness disease and preparation method thereof |
-
2000
- 2000-11-16 CN CN 00132276 patent/CN1130212C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1293973A (en) | 2001-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1836720A (en) | Chinese medicine composition for treating arthritis or gout and preparing method thereof | |
| WO2002078722A1 (en) | An antineoplastic drug | |
| CN104623201B (en) | A kind of liver protection Elmination of toxicant and fat-lowering hypoglycemic medicine and its application | |
| CN102397372A (en) | Medicinal composition and pharmaceutical preparation and application thereof to treating irritable bowel syndrome | |
| CN101590168B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN1201786C (en) | Traditional Chinese medicine composition for curing child's dyspepsia and cough and its preparing method | |
| CN1679864A (en) | Chinese medicine preparation for treating bronchitis | |
| CN106362020A (en) | Pine pollen composition with defaecation improving effect and preparation method of pine pollen | |
| CN1130212C (en) | Medicine for treating abdominal node and its preparing process | |
| CN1895546A (en) | Lycium chinensis polyose medicinal composition with therapeutic and health-care functions | |
| CN1724014A (en) | Extractive of total saponin of clematis root, prepn. method and pharmaceutical use thereof | |
| CN102727693B (en) | Compound propolis composition used for treating swine toxoplasmosis, and preparation method thereof | |
| CN1105557A (en) | Method for preparation of weight-loosing medicine and its products | |
| CN1199679C (en) | Medicine for nourishing yin and fortifying kidney, benefiting qi and fortifying spleen , and its preparation method | |
| CN101524447A (en) | Pharmaceutical composition for treating constipation and preparation process thereof | |
| CN104257809A (en) | Traditional Tibetan medicine for treating constipation | |
| CN103919972B (en) | A kind of pharmaceutical composition of resisting fatigue and its preparation method and application | |
| CN103142751A (en) | Traditional Chinese medicine composition for treating piglet iron-deficiency anemia | |
| CN1079396A (en) | Intelligence-enhancing pharmaceutical preparation | |
| CN102397510B (en) | Compound propolis composition for treating chicken Marek's disease and preparation method thereof | |
| CN1475261A (en) | Medicine for treating gastral cavity pain and its preparation method | |
| CN101194940A (en) | Anti-inflammation medicament for treating toothache and preparation method thereof | |
| CN1299755C (en) | Cinnamon compound medicine, and its preparing method and use | |
| CN1063077C (en) | Traditional Chinese medicine composition for lowering blood-lipid, and method for preparing same | |
| CN1126558C (en) | Medicine for treating kidney damage caused by immunological disease lupus erythematosus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| BB1A | Publication of application | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1064323 Country of ref document: HK |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20031210 Termination date: 20111116 |